

SDS Title: Azacitidine for Injection Safety Data Sheet	SDS Number: SDS-000037	Page Number: Page 1 of 15
Function: Regulatory Affairs	Effective Date: September 09, 2022	Version number: 2.0

Section 1. Identification

GHS product identifier : Azacitidine for Injection

Other means of identification : Not available.

Product type : Solid.

Relevant identified uses of the substance or mixture and uses advised against

Product use : Pharmaceuticals. (For intended use only.)
Observe technical data sheet/instructions for use.
Specific Treatments: Cancer, Anemia

Area of application : Professional applications.

Supplier's details : Meitheal Pharmaceuticals, Inc.
8700 W. Bryn Mawr, Suite 600S
Chicago, IL 60631

Telephone: 224-443-4617
www.meithealpharma.com

e-mail address of person responsible for this SDS : info@meithealpharma.com

Emergency telephone number (with hours of operation) : 844-824-8426 (Monday - Friday, 08:00 - 18:00 CST)

Section 2. Hazards identification

OSHA/HCS status : This material is considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200).

Classification of the substance or mixture : H302 ACUTE TOXICITY (oral) - Category 4
H315 SKIN IRRITATION - Category 2
H340 GERM CELL MUTAGENICITY - Category 1
H350 CARCINOGENICITY - Category 1B
H360 TOXIC TO REPRODUCTION - Category 1B
H362 TOXIC TO REPRODUCTION - Effects on or via lactation

GHS label elements

Hazard pictograms :



Signal word : Danger

SDS Title: Azacitidine for Injection Safety Data Sheet	SDS Number: SDS-000037	Page Number: Page 2 of 15
Function: Regulatory Affairs	Effective Date: September 09, 2022	Version number: 2.0

Section 2. Hazards identification

- Hazard statements** : H302 - Harmful if swallowed.
H315 - Causes skin irritation.
H340 - May cause genetic defects.
H350 - May cause cancer.
H360 - May damage fertility or the unborn child.
H362 - May cause harm to breast-fed children.
- Precautionary statements**
- Prevention** : P201 - Obtain special instructions before use.
P202 - Do not handle until all safety precautions have been read and understood.
P280 - Wear protective gloves, protective clothing and eye or face protection.
P263 - Avoid contact during pregnancy or while nursing.
P270 - Do not eat, drink or smoke when using this product.
P264 - Wash thoroughly after handling.
- Response** : P308 + P313 - IF exposed or concerned: Get medical advice or attention.
P301 + P312, P330 - IF SWALLOWED: Call a POISON CENTER or doctor if you feel unwell. Rinse mouth.
P362 + P364 - Take off contaminated clothing and wash it before reuse.
P302 + P352 - IF ON SKIN: Wash with plenty of water.
P332 + P313 - If skin irritation occurs: Get medical advice or attention.
- Storage** : P405 - Store locked up.
- Disposal** : P501 - Dispose of contents and container in accordance with all local, regional, national and international regulations.
- Hazards not otherwise classified** : None known.

Section 3. Composition/information on ingredients

- Substance/mixture** : Mixture
- Other means of identification** : Not available.

Ingredient name	Other names	%	CAS number
2-(β-D-ribofuranosyl)-4-amino-1,3,5-triazin-2-one	-	≥50 - ≤75	320-67-2
D-mannitol	Mannitol	≥50 - ≤75	69-65-8

Any concentration shown as a range is to protect confidentiality or is due to batch variation.

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified and hence require reporting in this section.

SDS Title: Azacitidine for Injection Safety Data Sheet	SDS Number: SDS-000037	Page Number: Page 3 of 15
Function: Regulatory Affairs	Effective Date: September 09, 2022	Version number: 2.0

Section 4. First aid measures

Description of necessary first aid measures

- Eye contact** : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention.
- Inhalation** : Remove victim to fresh air and keep at rest in a position comfortable for breathing. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
- Skin contact** : Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Get medical attention. Wash clothing before reuse. Clean shoes thoroughly before reuse.
- Ingestion** : Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention. If necessary, call a poison center or physician. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

Most important symptoms/effects, acute and delayed

Potential acute health effects

- Eye contact** : No known significant effects or critical hazards.
- Inhalation** : No known significant effects or critical hazards.
- Skin contact** : Causes skin irritation.
- Ingestion** : Harmful if swallowed.

Over-exposure signs/symptoms

- Eye contact** : Adverse symptoms may include the following:
pain or irritation
watering
redness
- Inhalation** : Adverse symptoms may include the following:
reduced fetal weight
increase in fetal deaths
skeletal malformations

SDS Title: Azacitidine for Injection Safety Data Sheet	SDS Number: SDS-000037	Page Number: Page 4 of 15
Function: Regulatory Affairs	Effective Date: September 09, 2022	Version number: 2.0

Section 4. First aid measures

- Skin contact** : Adverse symptoms may include the following:
irritation
redness
reduced fetal weight
increase in fetal deaths
skeletal malformations
- Ingestion** : Adverse symptoms may include the following:
reduced fetal weight
increase in fetal deaths
skeletal malformations

Indication of immediate medical attention and special treatment needed, if necessary

- Notes to physician** : In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
- Specific treatments** : No specific treatment.
- Protection of first-aiders** : No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

See toxicological information (Section 11)

Section 5. Fire-fighting measures

Extinguishing media

- Suitable extinguishing media** : Use dry chemical, CO₂, alcohol-resistant foam or water spray (fog).
- Unsuitable extinguishing media** : Do not use water jet.

Specific hazards arising from the chemical : No specific fire or explosion hazard.

- Hazardous thermal decomposition products** : Decomposition products may include the following materials:
carbon dioxide
carbon monoxide
nitrogen oxides
Emits toxic fumes when heated to decomposition.

Special protective actions for fire-fighters : Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.

Special protective equipment for fire-fighters : Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

SDS Title: Azacitidine for Injection Safety Data Sheet	SDS Number: SDS-000037	Page Number: Page 5 of 15
Function: Regulatory Affairs	Effective Date: September 09, 2022	Version number: 2.0

Section 6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

- For non-emergency personnel** : No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.
- For emergency responders** : If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

Environmental precautions : Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

Methods and materials for containment and cleaning up

- Small spill** : Move containers from spill area. Avoid dust generation. Do not dry sweep. Vacuum dust with equipment fitted with a HEPA filter and place in a closed, labeled waste container. Place spilled material in a designated, labeled waste container. Dispose of via a licensed waste disposal contractor.
- Large spill** : Move containers from spill area. Approach release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Avoid dust generation. Do not dry sweep. Vacuum dust with equipment fitted with a HEPA filter and place in a closed, labeled waste container. Dispose of via a licensed waste disposal contractor. Note: see Section 1 for emergency contact information and Section 13 for waste disposal.

Section 7. Handling and storage

Precautions for safe handling

- Protective measures** : Put on appropriate personal protective equipment (see Section 8). Avoid exposure - obtain special instructions before use. Avoid contact during pregnancy or while nursing. Do not handle until all safety precautions have been read and understood. Do not get in eyes or on skin or clothing. Do not ingest. If during normal use the material presents a respiratory hazard, use only with adequate ventilation or wear appropriate respirator. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container.
- Advice on general occupational hygiene** : Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

SDS Title: Azacitidine for Injection Safety Data Sheet	SDS Number: SDS-000037	Page Number: Page 6 of 15
Function: Regulatory Affairs	Effective Date: September 09, 2022	Version number: 2.0

Section 7. Handling and storage

Conditions for safe storage, including any incompatibilities : Store between the following temperatures: 20 to 25°C (68 to 77°F). Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Store locked up. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

Section 8. Exposure controls/personal protection

Control parameters

Occupational exposure limits

Ingredient name	Exposure limits
2-(β-D-ribofuranosyl)-4-amino- 1,3,5-triazin-2-one	None.
D-mannitol	None.

Appropriate engineering controls : If user operations generate dust, fumes, gas, vapor or mist, use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits.

Environmental exposure controls : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

Individual protection measures

Hygiene measures : Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: chemical splash goggles.

Skin protection

Hand protection : Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.

SDS Title: Azacitidine for Injection Safety Data Sheet	SDS Number: SDS-000037	Page Number: Page 7 of 15
Function: Regulatory Affairs	Effective Date: September 09, 2022	Version number: 2.0

Section 8. Exposure controls/personal protection

- Body protection** : Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
- Other skin protection** : Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
- Respiratory protection** : Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Section 9. Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

Appearance

- Physical state** : Solid.
- Color** : White to off-white.
- Odor** : Not available.
- Odor threshold** : Not available.
- pH** : 5.5 to 8 (reconstitution solution)
- Melting point** : Not available.
- Boiling point, initial boiling point, and boiling range** : 225 to 230°C (437 to 446°F)
- Flash point** : Not applicable.
- Evaporation rate** : Not available.
- Flammability** : Not available.
- Lower and upper explosion limit/flammability limit** : Not applicable.
- Vapor pressure** : Not available.
- Relative vapor density** : Not applicable.
- Relative density** : Not available.
- Density** : Not available.
- Solubility(ies)** :

Media	Result
cold water	Very slightly soluble
hot water	Very slightly soluble

Media	Result
cold water	Very slightly soluble
hot water	Very slightly soluble

- Miscible with water** : No.
- Partition coefficient: n-octanol/water** : Not applicable.
- Auto-ignition temperature** : Not applicable.
- Decomposition temperature** : Not available.
- SADT** : Not available.
- Viscosity** : Not applicable.

SDS Title: Azacitidine for Injection Safety Data Sheet	SDS Number: SDS-000037	Page Number: Page 8 of 15
Function: Regulatory Affairs	Effective Date: September 09, 2022	Version number: 2.0

Section 9. Physical and chemical properties

Flow time (ISO 2431) : Not available.

Particle characteristics

Median particle size : Not available.

Other information

Physical/chemical properties comments : No additional information.

Section 10. Stability and reactivity

Reactivity : No specific test data related to reactivity available for this product or its ingredients.

Chemical stability : The product is stable.

Possibility of hazardous reactions : Under normal conditions of storage and use, hazardous reactions will not occur.
Under normal conditions of storage and use, hazardous polymerization will not occur.

Conditions to avoid : Keep from freezing. Avoid inhalation of vapor, spray or mist.

Incompatible materials : Reactive or incompatible with the following materials: oxidizing materials, acids and alkalis.

Hazardous decomposition products : Under normal conditions of storage and use, hazardous decomposition products should not be produced.

Section 11. Toxicological information

Information on toxicological effects

Acute toxicity

Product/ingredient name	Result	Species	Dose	Exposure
D-mannitol	LD50 Oral	Rat	13500 mg/kg	-

Irritation/Corrosion
Not available.

Sensitization
Not available.

Mutagenicity

Conclusion/Summary : Not available.

Carcinogenicity

SDS Title: Azacitidine for Injection Safety Data Sheet	SDS Number: SDS-000037	Page Number: Page 9 of 15
Function: Regulatory Affairs	Effective Date: September 09, 2022	Version number: 2.0

Section 11. Toxicological information

Conclusion/Summary : Not available.

Classification

Product/ingredient name	OSHA	IARC	NTP
2-(β-D-ribofuranosyl)-4-amino-1,3,5-triazin-2-one	-	2A	Reasonably anticipated to be a human carcinogen.

Reproductive toxicity

Conclusion/Summary : Not available.

Teratogenicity

Conclusion/Summary : Not available.

Specific target organ toxicity (single exposure)

Not available.

Specific target organ toxicity (repeated exposure)

Not available.

Aspiration hazard

Not available.

Information on the likely routes of exposure : Routes of entry anticipated: Oral, Dermal, Inhalation.

Potential acute health effects

- Eye contact** : No known significant effects or critical hazards.
- Inhalation** : No known significant effects or critical hazards.
- Skin contact** : Causes skin irritation.
- Ingestion** : Harmful if swallowed.

Symptoms related to the physical, chemical and toxicological characteristics

- Eye contact** : Adverse symptoms may include the following:
pain or irritation
watering
redness
- Inhalation** : Adverse symptoms may include the following:
reduced fetal weight
increase in fetal deaths
skeletal malformations
- Skin contact** : Adverse symptoms may include the following:
irritation
redness
reduced fetal weight
increase in fetal deaths
skeletal malformations

SDS Title: Azacitidine for Injection Safety Data Sheet	SDS Number: SDS-000037	Page Number: Page 10 of 15
Function: Regulatory Affairs	Effective Date: September 09, 2022	Version number: 2.0

Section 11. Toxicological information

Ingestion : Adverse symptoms may include the following:
 reduced fetal weight
 increase in fetal deaths
 skeletal malformations

Delayed and immediate effects and also chronic effects from short and long term exposure

Short term exposure

Potential immediate effects : Not available.

Potential delayed effects : Not available.

Long term exposure

Potential immediate effects : Not available.

Potential delayed effects : Not available.

Potential chronic health effects

General : No known significant effects or critical hazards.

Carcinogenicity : May cause cancer. Risk of cancer depends on duration and level of exposure.

Mutagenicity : May cause genetic defects.

Reproductive toxicity : May damage fertility or the unborn child.
 May cause harm to breast-fed children.

Numerical measures of toxicity

Acute toxicity estimates

Product/ingredient name	Oral (mg/kg)	Dermal (mg/kg)	Inhalation (gases) (ppm)	Inhalation (vapors) (mg/l)	Inhalation (dusts and mists) (mg/l)
Azacitidine for Injection	1000	N/A	N/A	N/A	N/A
2-(β-D-ribofuranosyl)-4-amino- 1,3,5-triazin-2-one	500	N/A	N/A	N/A	N/A
D-mannitol	13500	N/A	N/A	N/A	N/A

Section 12. Ecological information

Toxicity

Conclusion/Summary : Not available.

Persistence and degradability

Not available.

SDS Title: Azacitidine for Injection Safety Data Sheet	SDS Number: SDS-000037	Page Number: Page 11 of 15
Function: Regulatory Affairs	Effective Date: September 09, 2022	Version number: 2.0

Section 12. Ecological information

Bioaccumulative potential

Product/ingredient name	LogP _{ow}	BCF	Potential
2-(β-D-ribofuranosyl)-4-amino-1,3,5-triazin-2-one	-3.83	-	low
D-mannitol	-3.1	-	low

Mobility in soil

Soil/water partition coefficient (K_{oc}) : Not available.

Other adverse effects : No known significant effects or critical hazards.

Section 13. Disposal considerations

Disposal methods : The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.

Section 14. Transport information

	DOT Classification	IMDG	IATA
UN number	Not regulated.	Not regulated.	Not regulated.
UN proper shipping name	-	-	-
Transport hazard class(es)	-	-	-
Packing group	-	-	-
Environmental hazards	No.	No.	No.

Additional information

SDS Title: Azacitidine for Injection Safety Data Sheet	SDS Number: SDS-000037	Page Number: Page 12 of 15
Function: Regulatory Affairs	Effective Date: September 09, 2022	Version number: 2.0

Section 14. Transport information

Special precautions for user : **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

Transport in bulk according to IMO instruments : Not available.

Section 15. Regulatory information

U.S. Federal regulations : **TSCA 8(a) CDR Exempt/Partial exemption:** Not determined
United States inventory (TSCA 8b): Not determined.

Clean Air Act Section 112 (b) Hazardous Air Pollutants (HAPs) : Not listed

Clean Air Act Section 602 Class I Substances : Not listed

Clean Air Act Section 602 Class II Substances : Not listed

DEA List I Chemicals (Precursor Chemicals) : Not listed

DEA List II Chemicals (Essential Chemicals) : Not listed

SARA 302/304

Composition/information on ingredients

No products were found.

SARA 304 RQ : Not applicable.

SARA 311/312

Classification : ACUTE TOXICITY (oral) - Category 4
SKIN IRRITATION - Category 2
GERM CELL MUTAGENICITY - Category 1
CARCINOGENICITY - Category 1B
TOXIC TO REPRODUCTION - Category 1B
TOXIC TO REPRODUCTION - Effects on or via lactation

Composition/information on ingredients

SDS Title: Azacitidine for Injection Safety Data Sheet	SDS Number: SDS-000037	Page Number: Page 13 of 15
Function: Regulatory Affairs	Effective Date: September 09, 2022	Version number: 2.0

Section 15. Regulatory information

Name	%	Classification
2-(β-D-ribofuranosyl)-4-amino-1,3,5-triazin-2-one	≥50 - ≤75	ACUTE TOXICITY (oral) - Category 4 SKIN IRRITATION - Category 2 GERM CELL MUTAGENICITY - Category 1B CARCINOGENICITY - Category 1B TOXIC TO REPRODUCTION - Category 1B TOXIC TO REPRODUCTION - Effects on or via lactation

SARA 313

Not applicable.

State regulations

Massachusetts : The following components are listed: 5-AZACYTIDINE

New York : None of the components are listed.

New Jersey : None of the components are listed.

Pennsylvania : None of the components are listed.

California Prop. 65

⚠ WARNING: This product can expose you to Azacitidine, which is known to the State of California to cause cancer. For more information go to www.P65Warnings.ca.gov.

Ingredient name	No significant risk level	Maximum acceptable dosage level
Azacitidine	-	-

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

SDS Title: Azacitidine for Injection Safety Data Sheet	SDS Number: SDS-000037	Page Number: Page 14 of 15
Function: Regulatory Affairs	Effective Date: September 09, 2022	Version number: 2.0

Section 16. Other information

Hazardous Material Information System (U.S.A.)

Health	*	4
Flammability		0
Physical hazards		0

Caution: HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. Although HMIS® ratings and the associated label are not required on SDSs or products leaving a facility under 29 CFR 1910.1200, the preparer may choose to provide them. HMIS® ratings are to be used with a fully implemented HMIS® program. HMIS® is a registered trademark and service mark of the American Coatings Association, Inc.

The customer is responsible for determining the PPE code for this material. For more information on HMIS® Personal Protective Equipment (PPE) codes, consult the HMIS® Implementation Manual.

National Fire Protection Association (U.S.A.)



Procedure used to derive the classification

Classification	Justification
ACUTE TOXICITY (oral) - Category 4	Calculation method
SKIN IRRITATION - Category 2	Calculation method
GERM CELL MUTAGENICITY - Category 1	Calculation method
CARCINOGENICITY - Category 1B	Calculation method
TOXIC TO REPRODUCTION - Category 1B	Calculation method
TOXIC TO REPRODUCTION - Effects on or via lactation	Calculation method

History

- Date of issue/Date of revision : 09/09/2022
- Date of previous issue : 09/11/2020
- Version : 2.0
- Prepared by : Sphera Solutions

Key to abbreviations

- : ATE = Acute Toxicity Estimate
- : AMP = Acceptable maximum peak above the acceptable ceiling concentration for an 8-hr shift
- : BCF = Bioconcentration Factor
- : GHS = Globally Harmonized System of Classification and Labelling of Chemicals
- : IATA = International Air Transport Association
- : IBC = Intermediate Bulk Container
- : IMDG = International Maritime Dangerous Goods
- : LogPow = logarithm of the octanol/water partition coefficient
- : MARPOL = International Convention for the Prevention of Pollution From Ships, 1973 as modified by the Protocol of 1978. ("Marpol" = marine pollution)



SDS Title: Azacitidine for Injection Safety Data Sheet	SDS Number: SDS-000037	Page Number: Page 15 of 15
Function: Regulatory Affairs	Effective Date: September 09, 2022	Version number: 2.0

Section 16. Other information

N/A = Not available
UN = United Nations

References

: HCS (U.S.A.)- Hazard Communication Standard
International transport regulations

✔ Indicates information that has changed from previously issued version.

Notice to reader

To the best of our knowledge, the information contained herein is accurate. However, neither the above-named supplier, nor any of its subsidiaries, assumes any liability whatsoever for the accuracy or completeness of the information contained herein.

Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.

Effective